Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
Solid Tumor
DRUG: ASCA101
Maximum tolerated dose(MTD), MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of dosing, 4weeks
Objective response rate(ORR), The proportion of patients achieving a partial response (PR) or complete response (CR) per RECIST 1.1, From first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14Jul2023]|Progression Free Survival(PFS), Time from first dose until disease progression or death using RECIST 1.1, From first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14Jul2023]|Duration of Response(DoR), Time from first PR or CR until disease progression or death using RECIST 1.1, From first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14Jul2023]
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.